Simultaneous Pharmacologic Inhibition of Yes-Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic-co-Glycolic) Acid-Encapsulated Microparticles Improves Pulmonary Hypertension.
Abhinav P. Acharya,Ying Tang,Thomas Bertero,Yi‐Yin Tai,Lloyd D. Harvey,Chen‐Shan C. Woodcock,Wei Sun,Ricardo Pineda,Nilay Mitash,Melanie Königshoff,Steven R. Little,Stephen Y. Chan
DOI: https://doi.org/10.1161/jaha.120.019091
IF: 6.106
2021-06-02
Journal of the American Heart Association
Abstract:Background Pulmonary hypertension (PH) is a deadly disease characterized by vascular stiffness and altered cellular metabolism. Current treatments focus on vasodilation and not other root causes of pathogenesis. Previously, it was demonstrated that glutamine metabolism, as catalyzed by GLS1 (glutaminase 1) activity, is mechanoactivated by matrix stiffening and the transcriptional coactivators YAP1 (yes‐associated protein 1) and transcriptional coactivator with PDZ‐binding motif (TAZ), resulting in pulmonary vascular proliferation and PH. Pharmacologic inhibition of YAP1 (by verteporfin) or glutaminase (by CB‐839) improved PH in vivo. However, systemic delivery of these agents, particularly YAP1 inhibitors, may have adverse chronic effects. Furthermore, simultaneous use of pharmacologic blockers may offer additive or synergistic benefits. Therefore, a strategy that delivers these drugs in combination to local lung tissue, thus avoiding systemic toxicity and driving more robust improvement, was investigated. Methods and Results We used poly(lactic‐co‐glycolic) acid polymer‐based microparticles for delivery of verteporfin and CB‐839 simultaneously to the lungs of rats suffering from monocrotaline‐induced PH. Microparticles released these drugs in a sustained fashion and delivered their payload in the lungs for 7 days. When given orotracheally to the rats weekly for 3 weeks, microparticles carrying this drug combination improved hemodynamic (right ventricular systolic pressure and right ventricle/left ventricle+septum mass ratio), histologic (vascular remodeling), and molecular markers (vascular proliferation and stiffening) of PH. Importantly, only the combination of drug delivery, but neither verteporfin nor CB‐839 alone, displayed significant improvement across all indexes of PH. Conclusions Simultaneous, lung‐specific, and controlled release of drugs targeting YAP1 and GLS1 improved PH in rats, addressing unmet needs for the treatment of this deadly disease. Nonstandard Abbreviations and Acronyms GLS1 glutaminase 1 PH pulmonary hypertension PLGA poly(lactic‐co‐glycolic) acid RVSP right ventricular systolic pressure TAZ transcriptional coactivator with PDZ‐binding motif YAP1 yes‐associated protein 1 Clinical Perspective What Is New? Simultaneous, lung‐specific, and controlled release of drugs targeting YAP1 (yes‐associated protein 1) and GLS1 (glutaminase 1) and encapsulated by poly(lactic‐co‐glycolic) acid polymer‐based microparticles act together to improve pulmonary hypertension in rats. Such targeted combinatorial therapy performs better across multiple indexes of disease than delivery of a poly(lactic‐co‐glycolic) acid polymer‐based single drug and at much lower doses than used for systemic administration. What Are the Clinical Implications? These results carry broad implications regarding the development of specific, next‐generation drug combinations for pulmonary vascular disease and perhaps for pulmonary conditions beyond pulmonary hypertension that affect both normal health and disease. Pulmonary hypertension (PH) is a poorly understood vascular disease with increasing prevalence worldwide but with inadequate treatment options. 1 There exist more than a dozen approved vasodilator drugs for treatment of this disease; nonetheless, mortality rates with current therapies remain high. At the cellular and molecular levels in the diseased pulmonary vasculature, PH is characterized by metabolic dysregulation, pro‐proliferative states, and adverse pulmonary vascular remodeling and stiffness. As such, there have been recent efforts to develop novel pharmacologic approaches that target the molecular origins of PH and thus could represent disease‐modifying opportunities. Recently, we reported a key molecular connection between vessel stiffness and metabolic dysregulation that promotes PH. Namely, we found that vessel stiffness mechanoactivates the YAP1 (yes‐associated protein 1)/TAZ (transcriptional coactivato -Abstract Truncated-
cardiac & cardiovascular systems